McSAF is a Contract Research Organisation (CRO) specialized in Bio-Organic & Bio-Conjugates Chemistry, with specific focus onto providing comprehensive chemistry services to BIO industries.
As a partner of choice for Biopharmaceutical, Animal Health & Diagnostic Companies, McSAF is mainly involved in custom complex synthesis, chemical optimization & bio-molecular targeting.
Its core expertise covers Therapeutic Peptides and Proteins, Antibodies, and Drug Conjugates.
Its team has a strong background in synthetic selective chemistry, and a real expertise in bioconjugation, including specific designs of Antibody Drug Conjugates (ADCs) with own proprietary coupling technology.
McSAF’s innovative coupling technology allows the generation of homogeneous Antibody Drug Conjugates, by a real control of DAR (Drug to Antibody Ratio) without modification of the native antibody structure.
This unique site-specific technology overpass then competing ones by
- Leading to a unique & homogenous ADC of a defined DAR
- Maintaining the antibody native structure (SS-bond reconstruction)
- Avoiding amino-acid introduction in the bio-production process
- Minimizing the toxin plasma release and then the off-target toxicity by a great coupling stability
Further details and enquiries : email@example.com
Articles liés à McSAF
Il n'y a aucun actualité reliée à cet établissement